FDA will delay Moderna use for children 12 to 17 to evaluate myocarditis risk until at least January

Moderna says FDA will delay its vaccine use for children aged 12 to 17 to continue evaluations of myocarditis risk - or inflammation of the heart muscle - until at least January 2022.

Related Keywords

United States ,New York ,Japan ,North Carolina ,Massachusetts ,Washington ,Sweden ,Finland ,Cambridge ,Cambridgeshire ,United Kingdom ,American ,Lydia Melo ,Centers For Disease ,Pfizer ,New York Times ,Washington Post ,Duke University In Durham ,Moderna Friday ,Duke University ,Disease Control ,Dailymail ,News ,Moderna ,Fda ,Coronavirus ,